Current Cancer Diagnostics Market Timeline
Global cancer diagnostics companies are advancing multi-cancer early detection (MCED) blood tests, with Grail's Galleri test already commercially available in the United States and United Kingdom as of the latest public data. Guardant Health expanded its Shield colorectal cancer screening test to U.S. laboratories in 2024, following FDA clearance. Freenome completed its PREEMPT CRC pivotal trial enrollment in 2024, targeting FDA approval for its multi-cancer early detection test. These timelines reflect a shift toward routine blood-based screening in average-risk populations, with analysts projecting the MCED market to grow significantly through the end of the decade multi-cancer early detection market growth.
Regulatory timelines remain compressed as agencies prioritize oncology tools. The FDA granted Breakthrough Device Designation to several MCED platforms, shortening review windows. Guardant Health's Shield received FDA clearance in 2024 after a streamlined review process. The Centers for Medicare & Medicaid Services (CMS) finalized coverage pathways for MCED tests under the Medicare Learning Network, enabling broader patient access by 2025. These decisions signal that cancer diagnostics will become a standard part of preventive care within the next 12 to 24 months FDA Breakthrough Device program.
Cancer Treatment Approvals and Pipeline Milestones
The oncology pipeline is dominated by antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), and personalized cancer vaccines. Moderna and Merck's individualized neoantigen mRNA-4157 (V940) melanoma vaccine entered Phase 3 trials in 2023, with pivotal data expected by 2026. Pfizer's ADC datopotamab deruxtecan received FDA accelerated approval for HR-positive/HER2-negative metastatic breast cancer in 2024. Gilead Sciences' Trodelvy (sacituzumab govitecan) expanded to earlier treatment lines after positive Phase 3 results in triple-negative breast cancer FDA cancer drug approvals database.
Approval timelines for cell therapies are accelerating. Caribou Biosciences' CB-010 anti-CD19 CAR-T therapy received FDA Fast Track designation for relapsed or refractory B-cell non-Hodgkin lymphoma in 2024. Johnson & Johnson's CAR-T candidate cilta-cel (ciltacabtagene autoleucel) maintains its position as a leading treatment for multiple myeloma following FDA approval in 2022. Companies are targeting 2025 to 2027 for next-generation solid tumor CAR-T approvals, with preclinical data now showing tumor microenvironment engineering breakthroughs CAR-T therapy market expansion.
Cancer Drug Pricing and Market Access Trends
New oncology drugs continue to command premium pricing, with annual list costs for novel targeted therapies and immunotherapies often exceeding $200,000 per year. The Inflation Reduction Act (IRA) of 2022 introduced Medicare drug price negotiation provisions, with the first batch of selected drugs announced in 2023, though most cancer therapies were excluded from the initial cycle. CMS finalized a 2025 rule expanding the